drugset / Trial / NCT03588975

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

NCT03588975 ↗

Phase 3 Recruiting 45 enrolled Vericel Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Timeline

Start
2018-10-24
Primary completion
2030-02
Completion
2030-02

Drugs

EvaluationDrugModalityDoseRoute
Subject MACI Cell therapy — Other